<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04525495</url>
  </required_header>
  <id_info>
    <org_study_id>DPMSNUH</org_study_id>
    <nct_id>NCT04525495</nct_id>
  </id_info>
  <brief_title>Dopamine in Neonate</brief_title>
  <official_title>Pharmacokinetic and Pharmacodynamic Study of Sildenafil in Neonates and Preterm Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the pharmacokinetics and pharmacodynamics of&#xD;
      dopamine which is used as treatment of hypotension in neonate and preterm infant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steady state concentration of dopamine (Css) at 2mcg/kg/min</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 2mcg/kg/min</time_frame>
    <description>dopamine drug level in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady state concentration of dopamine (Css) at 5mcg/kg/min</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 5mcg/kg/min</time_frame>
    <description>dopamine drug level in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady state concentration of dopamine (Css) at 10mcg/kg/min</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 10mcg/kg/min</time_frame>
    <description>dopamine drug level in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady state concentration of dopamine (Css) at 15mcg/kg/min</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 15mcg/kg/min</time_frame>
    <description>dopamine drug level in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady state concentration of dopamine (Css) at 20mcg/kg/min</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 20mcg/kg/min</time_frame>
    <description>dopamine drug level in blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure in mmHg at 2mcg/kg/min</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 2mcg/kg/min</time_frame>
    <description>Systolic, diastolic and mean blood pressure in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure in mmHg at 5mcg/kg/min</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 5mcg/kg/min</time_frame>
    <description>Systolic, diastolic and mean blood pressure in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure in mmHg at 10mcg/kg/min</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 10mcg/kg/min</time_frame>
    <description>Systolic, diastolic and mean blood pressure in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure in mmHg at 10mcg/kg/min</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 20mcg/kg/min</time_frame>
    <description>Systolic, diastolic and mean blood pressure in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 2mcg/kg/min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 5mcg/kg/min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 10mcg/kg/min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 15mcg/kg/min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 20mcg/kg/min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction from Echocardiography</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 2mcg/kg/min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction from Echocardiography</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 5mcg/kg/min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction from Echocardiography</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 10mcg/kg/min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction from Echocardiography</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 15mcg/kg/min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction from Echocardiography</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 20mcg/kg/min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional shortening from Echocardiography</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 2mcg/kg/min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional shortening from Echocardiography</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 5mcg/kg/min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional shortening from Echocardiography</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 10mcg/kg/min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional shortening from Echocardiography</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 15mcg/kg/min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional shortening from Echocardiography</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 20mcg/kg/min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tei index from Echocardiography</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 2mcg/kg/min</time_frame>
    <description>(Mitral valve closure to opening time(ms)-LV ejection time(ms))/LV ejection time(ms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tei index from Echocardiography</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 5mcg/kg/min</time_frame>
    <description>(Mitral valve closure to opening time(ms)-LV ejection time(ms))/LV ejection time(ms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tei index from Echocardiography</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 10mcg/kg/min</time_frame>
    <description>(Mitral valve closure to opening time(ms)-LV ejection time(ms))/LV ejection time(ms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tei index from Echocardiography</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 15mcg/kg/min</time_frame>
    <description>(Mitral valve closure to opening time(ms)-LV ejection time(ms))/LV ejection time(ms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tei index from Echocardiography</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 20mcg/kg/min</time_frame>
    <description>(Mitral valve closure to opening time(ms)-LV ejection time(ms))/LV ejection time(ms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VTI (velocity time integral) from Echocardiography</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 2mcg/kg/min</time_frame>
    <description>the area within the spectral curve and indicates how far blood travels during the flow period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VTI (velocity time integral) from Echocardiography</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 5mcg/kg/min</time_frame>
    <description>the area within the spectral curve and indicates how far blood travels during the flow period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VTI (velocity time integral) from Echocardiography</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 10mcg/kg/min</time_frame>
    <description>the area within the spectral curve and indicates how far blood travels during the flow period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VTI (velocity time integral) from Echocardiography</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 15mcg/kg/min</time_frame>
    <description>the area within the spectral curve and indicates how far blood travels during the flow period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VTI (velocity time integral) from Echocardiography</measure>
    <time_frame>After continuous infusion for more than 30 minutes at 20mcg/kg/min</time_frame>
    <description>the area within the spectral curve and indicates how far blood travels during the flow period</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neonates and Preterm Infants</condition>
  <arm_group>
    <arm_group_label>Dopamine treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dopamine</intervention_name>
    <description>Dopamine treatment</description>
    <arm_group_label>Dopamine treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Admitted at NICU in Seoul National University Hospital, Seoul Asan Hospital or&#xD;
             Severance Hospital&#xD;
&#xD;
          -  Infants who were diagnosed with hypotension&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Congenital heart disease&#xD;
&#xD;
          -  Chromosomal anomaly&#xD;
&#xD;
          -  Treated with ECMO or CRRT&#xD;
&#xD;
          -  Arrhythmia&#xD;
&#xD;
          -  Hypovolemic state&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Month</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Han-Suk Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Children's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2020</study_first_posted>
  <last_update_submitted>August 20, 2020</last_update_submitted>
  <last_update_submitted_qc>August 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

